摘要
目的:观察急性冠脉综合征((ACS)发生后应用不同剂量阿托伐他汀的疗效与安全性。方法:将84例ACS患者随机分成两组,分别给予阿托伐他汀治疗。治疗组阿托伐他汀80 mg/d,每晚1次,两周后改为20 mg/d;对照组阿托伐他汀20 mg/d,每晚1次。观察3个月两组患者血脂水平及心血管事件的发生率和药物不良反应。结果:两组治疗3个月后的总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高敏C反应蛋白(hs-CRP)水平显著降低,且治疗组优于对照组。结论:ACS患者早期强化降脂可减少心血管事件发生,治疗过程中无严重不良反应。
Objective： To observe the clinical therapeutic effect and safety of dose-respanse atorvastatin on acute coronary syndrome.Methods： A total of 84 cases of acute coronary syndrome were randomly divided into two groups.They were treated with atorvastatin.Atorvastatin administered subgroup were treated with atorvastatin（80 mg/d qN po） for 2 weeks,and then they were treated with atorvastatin（20 mg/d qN po）.At the same time,patients in observation group were treated with atorvastatin（20 mg/d,qN po）.After 3 months we compare level of blood lipid,cardiac events and safety of atorvastatin.Results： After 3 months tota1 cholestero1（TC）,low density 1ipoprotein cholestero1（LDL-C） and high-sensitivity C-reactive protein（hs-CRP） were significantly reduced in two groups.But the administered subgroup is more efficacious than observation group.Conclusion： Intensive lipid lowering is safe and effective in pantients of acute coronary syndrome.
出处
《河南医学研究》
CAS
2010年第4期419-421,共3页
Henan Medical Research
关键词
急性冠脉综合征
阿托伐他汀
低密度脂蛋白
高敏C反应蛋白
acute coronary syndrome
atorvastatin
low density lipoprotein cholesterol
high-sensitivity C-reactive protein
